No Data
No Data
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$142.5K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 64,568 shares of common stock on Jun 27, 28, 2024 at an average price of $2.207 for a total value of $142.5K.Source: Announ
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$28,734.32 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 12,725 shares of common stock on Jun 25, 2024 at an average price of $2.2581 for a total value of $28,734.32.Source: Announ
Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$44,007.97 in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 15,054 shares of common stock on May 30, 31, 2024 at an average price of $2.9233 for a total value of $44,007.97.Source: An
Protara Therapeutics(TARA.US) 10% Shareholder Sells US$130.43K in Common Stock
$Protara Therapeutics(TARA.US)$ 10% Shareholder Opaleye Management Inc. sold 42,800 shares of common stock on May 21, 22, 2024 at an average price of $3.0475 for a total value of $130.43K.Source: Anno